GAUDIUM IVF N WOMEN H L Share price

Gaudium IVF and Women Health Limited was originally incorporated in the name of 'Gaudium IVF and Women Health Private Limited' as a Private Limited Company, dated March 24, 2015 with the RoC, Delhi and Haryana. Subsequently, the status of the Company was converted from a Private Limited into a Public Limited and the name was changed to Gaudium IVF and Women Health Limited', and a fresh Certificate of Incorporation dated October 24, 2024 was issued by the Central Processing Center. Company is engaged in IVF (In vitro fertilization) treatment in India and has grown into several states with Hub and spoke model over the years. Gaudium IVF is founded by the Promoter Dr. Manika Khanna, a specialist with advanced training in gynecological endoscopic surgery from Kiel, Germany, and in Gynaec Endoscopy from Melbourne IVF Gujarat Private Limited. The Company offer a complete array of specialized fertility and reproductive health services. Their treatments include In Vitro Fertilization (IVF), Intracytoplasmic Sperm Injection (ICSI), Intrauterine Insemination (IUI) and ovulation induction, all treatment is carefully designed to address a variety of infertility challenges for both male and female. Its facilities provide a comprehensive range of male infertility treatments, including advanced sperm retrieval techniques. For fertility preservation, Company offer cryopreservation services for eggs freezing for future fertilization, utilizing advanced technology to ensure optimal success rates in future IVF cycles. It further provide laparoscopic and hysteroscopic surgeries for the diagnosis and treatment of infertility-related conditions, as well as genetic testing options, including Preimplantation Genetic Testing (PGT), designed to enhance pregnancy outcomes and mitigate the risks of genetic disorders. The Company began its journey by starting the business operations at Gaudium Hospital in 2019. Gaudium IVF and Gynae Solutions, a proprietary firm of Dr. Manika Khanna, was acquired by the Company with the main object clause, pursuant to a preferential allotment dated March 29, 2021. This acquisition was executed through the issuance of 9,40,232 equity shares. In 2024, Company has started Srinagar Centre in Jammu & Kashmir; started Banglore Centre in Karnataka. The Company offer a complete specialized fertility and reproductive health services. The advance treatments include In Vitro Fertilization (IVF), Intracytoplasmic Sperm Injection (ICSI), Intrauterine Insemination (IUI), and ovulation induction, all our treatment is carefully designed to address a variety of infertility challenges for both male and female. It also offers comprehensive gynecological care, including PCOD/PCOS and endometriosis. Further, high-risk pregnancy management is provided for women with complex fertility histories or health conditions. The wellness aspect includes fertility wellness programs, offering nutritional counselling and psychological support to ensure holistic care for couples undergoing treatments. Apart from these, the facilities provide a comprehensive range of male infertility treatments, including advanced sperm retrieval techniques. For fertility preservation, Company offer cryopreservation services for eggs freezing for future fertilization, utilizing state-of-the-art technology to ensure optimal success rates in future IVF cycles. Additionally, the centers specialize in Frozen Embryo Transfers (FET). They also offer laparoscopic and hysteroscopic surgeries for diagnosis and treatment of infertility-related conditions, as well as genetic testing options, including Preimplantation Genetic Testing (PGT), designed to enhance pregnancy outcomes and mitigate the risks of genetic disorders. The Company came up with IPO of 2,08,86,200 equity shares of Rs 5 each by raising funds aggregating to Rs 165 crores, comprising a fresh issue of 1,13,92,500 equity shares amounting to Rs 90 crores and the offer for sale of 94,93,700 equity shares amounting to Rs 75 crores on February 24, 2026.